Hims & Hers Health, Inc. Reports Record Fourth Quarter and Full Year 2022 Financial Results

February 27, 2023

Full year 2022 revenue of $526.9 million, up 94% year-over-year

Q4 2022 record revenue of $167.2 million, up 97% year-over-year

Q4 2022 net loss of $10.9 million and achieves Adjusted EBITDA profitability of $3.9 million

Eclipses one million subscribers at year end, up 88% year-over-year

Provides Q1 and full year 2023 guidance, with full year 2023 revenue in the range of $735 million to $755 million and Adjusted EBITDA in the range of $20 million to $30 million

Introduces 2025 targets of at least $1.2 billion in revenue and $100 million in Adjusted EBITDA

Hims & Hers Health, Inc. (“Hims & Hers” or the “Company”) (NYSE: HIMS), the leading health and wellness platform, today reported financial results for the fourth quarter and full year ended December 31, 2022.

“2022 was a year of outstanding execution across the company, as we surpassed one million Subscribers on the platform and made significant strides in delivering on our mission to make the world feel great through the power of better health,” said Andrew Dudum, co-founder and CEO. “New technological advancements, acquisition of key talent, ongoing brand strength, and operational excellence fueled strong growth across the business. We entered 2023 with tremendous momentum and are poised to drive top-line growth and profitability as we focus on four strategic pillars: building a trusted brand, deploying leading technology, developing innovative products and services, and ensuring clinical excellence, which will enable us to continue to execute on our mission and extend our reach.”

“We are excited by the large market opportunity in front of us. It is clear that our operating model is fueling strong results and momentum. Notably, the transition to positive Adjusted EBITDA in the fourth quarter provides us with additional flexibility to continue building scale,” said Yemi Okupe, CFO. “With the strong foundation we have laid and our track record of operational excellence, we are well-positioned to deliver on the 2023 outlook and longer term goals we’re introducing today.”

Key Business Metrics
(In Thousands, Except for Monthly Online Revenue per Average Subscriber and AOV, Unaudited)

 

Three Months Ended

D ecember 31,

 

Year Ended

D ecember 31,

 

2022

 

2021

 

% Change

 

2022

 

2021

 

% Change

 

 

 

 

 

 

 

 

 

 

 

 

Subscribers (end of period)

 

1,040

 

 

554

 

88

%

 

 

1,040

 

 

554

 

88

%

Monthly Online Revenue per Average Subscriber

$

55

 

 

$

50

 

 

10

%

 

$

53

 

 

$

51

 

 

4

%

 

 

 

 

 

 

 

 

 

 

 

 

Subscriptions (end of period)

 

1,116

 

 

 

609

 

 

83

%

 

 

1,116

 

 

 

609

 

 

83

%

Net Orders

 

1,855

 

 

 

1,063

 

 

75

%

 

 

6,122

 

 

 

3,504

 

 

75

%

AOV

$

87

 

 

$

74

 

 

18

%

 

$

82

 

 

$

74

 

 

11

%

Revenue
(In Thousands, Unaudited)

 

Three Months Ended

D ecember 31,

 

Year Ended

D ecember 31,

 

2022

 

2021

 

% Change

 

2022

 

2021

 

% Change

 

 

 

 

 

 

 

 

 

 

 

 

Online Revenue

$

161,162

 

$

78,312

 

106

%

 

$

502,507

 

$

259,170

 

94

%

Wholesale Revenue

 

6,041

 

 

 

6,387

 

 

(5

)%

 

 

24,409

 

 

 

12,708

 

 

92

%

Total revenue

$

167,203

 

 

$

84,699

 

 

97

%

 

$

526,916

 

 

$

271,878

 

 

94

%

Please see the discussion in “Revenue and Key Business Metrics” in Item 7 (Management’s Discussion & Analysis of Financial Condition and Results of Operations) of Part II of our Annual Report on Form 10-K for the fiscal year ended December 31, 2022 for a discussion of recent and upcoming changes to our key business metrics.

Fourth Quarter 2022 Financial Highlights

  • Revenue was $167.2 million for the fourth quarter of 2022 compared to $84.7 million for the fourth quarter of 2021, an increase of 97% year-over-year.
  • Gross margin was 79% for the fourth quarter of 2022 compared to 73% for the fourth quarter of 2021.
  • Net loss was $(10.9) million in the fourth quarter of 2022 compared to $(31.2) million for the fourth quarter of 2021.
  • Adjusted EBITDA was $3.9 million for the fourth quarter of 2022 compared to $(7.1) million for the fourth quarter of 2021.

Full Year 2022 Financial Highlights

  • Revenue was $526.9 million for the year ended December 31, 2022 compared to $271.9 million for the year ended December 31, 2021, an increase of 94% year-over-year.
  • Gross margin was 78% for the year ended December 31, 2022 compared to 75% for the year ended December 31, 2021.
  • Net loss was $(65.7) million for the year ended December 31, 2022 compared to $(107.7) million for the year ended December 31, 2021.
  • Adjusted EBITDA was $(15.8) million for the year ended December 31, 2022 compared to $(30.1) million for the year ended December 31, 2021.

A reconciliation of Adjusted EBITDA, a non-GAAP measure, to net loss, its most comparable financial measure under generally accepted accounting principles in the United States (“U.S. GAAP”), has been provided in this press release in the accompanying tables. Additional information about Adjusted EBITDA is also included below under the heading “Non-GAAP Financial Measures.”

2023 Financial Outlook

Hims & Hers is providing the following 2023 guidance:

For the first quarter 2023, we expect:

  • Revenue of $175 million to $180 million.
  • Adjusted EBITDA of $3 million to $6 million, reflecting an Adjusted EBITDA margin of 2% to 3%.

For the full year 2023, we expect:

  • Revenue of $735 million to $755 million.
  • Adjusted EBITDA of $20 million to $30 million, reflecting an Adjusted EBITDA margin of 3% to 4%.

2025 Financial Targets

Hims & Hers has demonstrated a consistent track record of execution driven by the strength of its business model and operational excellence, which is fueling strong top line growth and Adjusted EBITDA profitability. Given its large market opportunity and growing customer demand, the Company is providing financial targets for the full year 2025, which include:

  • Revenue of at least $1.2 billion.
  • Adjusted EBITDA of at least $100 million.

The guidance and targets provided above constitute forward-looking statements and actual results may differ materially. Refer to the “Cautionary Note Regarding Forward-Looking Statements” safe harbor section below for information on the factors that could cause our actual results to differ materially from these forward-looking statements.

We have not reconciled forward-looking Adjusted EBITDA to its most directly comparable U.S. GAAP measure, net loss, because we cannot predict with reasonable certainty the ultimate outcome of certain components of such reconciliations, including market-related assumptions that are not within our control, or others that may arise, without unreasonable effort. For these reasons, we are unable to assess the probable significance of the unavailable information, which could materially impact the amount of future net loss. See “Non-GAAP Financial Measures” for additional important information regarding Adjusted EBITDA.

Conference Call

Hims & Hers will host a conference call to review the fourth quarter and full year 2022 results on February 27, 2023, at 5:00 p.m. ET. The conference call can be accessed by dialing +1 (888) 510-2630 for U.S. participants and +1 (646) 960-0137 for international participants, and referencing conference ID #1704296. A live audio webcast will be available online at https://investors.forhims.com/. A replay of the call will be available via webcast for on-demand listening shortly after the completion of the call at the same link.

About Hims & Hers Health, Inc.

Hims & Hers is the leading health and wellness platform on a mission to help the world feel great through the power of better health.

We believe how you feel in your body and mind transforms how you show up in life. That’s why we’re building a future where nothing stands in the way of harnessing this power. Hims & Hers normalizes health & wellness challenges—and innovates on their solutions—to make feeling happy and healthy easy to achieve. No two people are the same, so the Company provides access to personalized care designed for results.

For more information, please visit https://investors.forhims.com/.

Cautionary Note Regarding Forward-Looking Statements

This press release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements can be identified by the use of forward-looking terminology, including the words “believe,” “estimate,” “anticipate,” “expect,” “assume,” “imply,” “intend,” “plan,” “may,” “will,” “potential,” “project,” “predict,” “continue,” “could,” or “should,” or, in each case, their plural, their negative or other variations or comparable terminology. There can be no assurance that actual results will not materially differ from expectations. Such statements include, but are not limited to, any statements relating to our financial outlook and guidance, including our mission to drive top-line growth and profitability and our ability to attain our long-term financial targets; our expected future financial and business performance, including with respect to the Hims & Hers platform, our marketing campaigns, our market opportunity, investments in innovation, and our infrastructure, and the underlying assumptions with respect to the foregoing; statements relating to events and trends relevant to us, including with respect to our financial condition, results of operations, short- and long-term business operations, objectives, and financial needs; expectations regarding our mobile applications, market acceptance, user experience, customer retention, our ability to invest and generate a return on any such investment, customer acquisition costs, operating efficiencies, the success of our business model, our ability to scale our business, the growth of certain of our categories and the impact of our acquisitions, our ability to expand the scope of our offerings and experiences, and our ability to comply with the extensive, complex and evolving regulatory requirements applicable to our business, including without limitation state and federal healthcare, privacy and consumer product quality laws and regulations. These statements are based on management’s current expectations, but actual results may differ materially due to various factors.

The forward-looking statements contained in this press release are based on our current expectations and beliefs concerning future developments and their potential effects on us. Future developments affecting us may not be those that we have anticipated. These forward-looking statements involve a number of risks, uncertainties (some of which are beyond our control) and other assumptions that may cause actual results or performance to be materially different from those expressed or implied by these forward-looking statements. These risks and uncertainties include, but are not limited to, those factors described in the “Risk Factors” section of each of our most recently filed Quarterly Report on Form 10-Q, our most recently filed Annual Report on Form 10-K, and any of our subsequent filings with the Securities and Exchange Commission (the “Commission”).

Should one or more of these risks or uncertainties materialize, or should any of our assumptions prove incorrect, actual results may vary in material respects from those projected in these forward-looking statements. We undertake no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required under applicable securities laws.

By their nature, forward-looking statements involve risks and uncertainties because they relate to events and depend on circumstances that may or may not occur in the future. We caution you that forward-looking statements are not guarantees of future performance and that our actual results of operations, financial condition and liquidity, and developments in the industry in which we operate may differ materially from those made in or suggested by the forward-looking statements contained in reports we have filed or will file with the Commission, including our most recently filed Annual Report on Form 10-K, our most recently filed Quarterly Report on Form 10-Q, and any of our subsequent filings with the Commission. In addition, even if our results of operations, financial condition and liquidity, and developments in the industry in which we operate are consistent with the forward-looking statements contained in such reports, those results or developments may not be indicative of results or developments in subsequent periods.

Key Business Metrics

As our business grows and evolves, we continually and strategically review our key metrics. Beginning with our 2022 Annual Report on Form 10-K, we commenced reporting “Subscribers” and “Monthly Online Revenue Per Average Subscriber” as additional key business metrics (as defined below). As a result of broadening the number of health and wellness categories the Company serves, we believe it is important to measure the holistic relationship that we have with our customers. Additionally, the recurring nature of our revenue necessitates the need for metrics that provide greater visibility into both the breadth and engagement of users on our platform. We believe Subscribers represent a more accurate reflection of the number of distinct users that we have on our platform relative to the number of subscriptions, and beginning with the three months ending March 31, 2023, we anticipate no longer reporting “Subscriptions” as a key business metric. Monthly Online Revenue per Average Subscriber reflects how users’ engagement with products across our platform is evolving. These changes are intended to better align our key business metrics with our internal priorities and business plans.

“Online Revenue” represents the sales of products and services on our platform, net of refunds, credits, and chargebacks, and includes revenue recognition adjustments recorded pursuant to U.S. GAAP, primarily relating to deferred revenue and returns reserve. Online Revenue is generated by selling directly to consumers through our websites and mobile applications. Our Online Revenue consists of products and services purchased by customers directly through our online platform. The majority of our Online Revenue is subscription-based, where customers agree to be billed on a recurring basis to have products and services automatically delivered to them.

“Wholesale Revenue” represents non-prescription product sales to retailers through wholesale purchasing agreements. We sell only non-prescription products to wholesale partners. In addition to being revenue generative and profitable, wholesale partnerships have the added benefit of generating brand awareness with new customers in physical environments.

“Subscribers” are customers who have one or more Subscriptions pursuant to which they have agreed to be automatically billed on a recurring basis at a defined cadence.

“Monthly Online Revenue per Average Subscriber” is defined as Online Revenue divided by “Average Subscribers,” which amount is then further divided by the number of months in a period. “Average Subscribers” are calculated as the sum of the Subscribers at the beginning and end of a given period divided by 2.

“Subscriptions” are defined as the number of customer agreements where the customer has agreed to be automatically billed on a recurring basis at a defined cadence. The billing cadence is typically defined as a number of months (for example, billed every month or every three months). Subscriptions are excluded from our reporting when payment has not occurred at the contracted billing cadence. Subscription billing is preferred by many of our customers because most of the products and services we make available are most effective when taken consistently and continuously. Customers can cancel subscriptions in between billing periods to stop receiving additional products and services and can reactivate subscriptions to continue receiving additional products and services. Subscriptions are sometimes also referred to by us as “subscription memberships” or “memberships.”

“Net Orders” are defined as the number of online customer orders minus transactions related to refunds, credits, chargebacks, and other negative adjustments. Net Orders represent transactions made on our platform during a defined period of time and exclude revenue recognition adjustments recorded pursuant to U.S. GAAP.

Average Order Value (“AOV”) is defined as Online Revenue divided by Net Orders (each as defined above).

CONDENSED CONSOLIDATED BALANCE SHEETS

(In Thousands, Except Share and Per Share Data, Unaudited)

 

 

December 31,

 

2022

 

2021

Assets

 

 

 

Current assets:

 

 

 

Cash and cash equivalents

$

46,772

 

 

$

71,784

 

Short-term investments

 

132,853

 

 

 

175,490

 

Inventory

 

21,562

 

 

 

13,558

 

Prepaid expenses and other current assets

 

15,408

 

 

 

9,073

 

Total current assets

 

216,595

 

 

 

269,905

 

Restricted cash

 

856

 

 

 

856

 

Goodwill

 

110,881

 

 

 

110,881

 

Intangibles, net

 

21,841

 

 

 

25,890

 

Operating lease right-of-use assets

 

4,936

 

 

 

5,111

 

Other long-term assets

 

11,232

 

 

 

7,942

 

Total assets

$

366,341

 

 

$

420,585

 

Liabilities and stockholders' equity

 

 

 

Current liabilities:

 

 

 

Accounts payable

$

32,363

 

 

$

19,640

 

Accrued liabilities

 

12,448

 

 

 

12,194

 

Deferred revenue

 

1,472

 

 

 

3,188

 

Earn-out payable

 

 

 

 

42,834

 

Operating lease liabilities

 

1,658

 

 

 

1,365

 

Total current liabilities

 

47,941

 

 

 

79,221

 

Operating lease liabilities

 

3,649

 

 

 

4,117

 

Earn-out liabilities

 

2,975

 

 

 

1,999

 

Other long-term liabilities

 

35

 

 

 

629

 

Total liabilities

 

54,600

 

 

 

85,966

 

Commitments and contingencies

 

 

 

Stockholders' equity:

 

 

 

Common stock – Class A shares, par value $0.0001, 2,750,000,000 shares authorized and 200,051,689 and 196,414,363 shares issued and outstanding as of December 31, 2022 and 2021, respectively; Class V shares, par value $0.0001, 10,000,000 shares authorized and 8,377,623 shares issued and outstanding as of December 31, 2022 and 2021

 

21

 

 

 

20

 

Additional paid-in capital

 

656,626

 

 

 

613,687

 

Accumulated other comprehensive loss

 

(277

)

 

 

(137

)

Accumulated deficit

 

(344,629

)

 

 

(278,951

)

Total stockholders' equity

 

311,741

 

 

 

334,619

 

Total liabilities and stockholders' equity

$

366,341

 

 

$

420,585

 

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS

(In Thousands, Except Share and Per Share Data, Unaudited)

 

 

 

Three Months Ended

D ecember 31,

 

Year Ended

D ecember 31,

 

 

2022

 

2021

 

2022

 

2021

Revenue

 

$

167,203

 

 

$

84,699

 

 

$

526,916

 

 

$

271,878

 

Cost of revenue

 

 

34,866

 

 

 

22,601

 

 

 

118,194

 

 

 

67,384

 

Gross profit

 

 

132,337

 

 

 

62,098

 

 

 

408,722

 

 

 

204,494

 

Gross margin %

 

 

79

%

 

 

73

%

 

 

78

%

 

 

75

%

Operating expenses:(1)

 

 

 

 

 

 

 

 

Marketing

 

 

85,542

 

 

 

42,707

 

 

 

272,587

 

 

 

135,902

 

Operations and support

 

 

22,521

 

 

 

13,845

 

 

 

77,403

 

 

 

47,593

 

Technology and development

 

 

8,311

 

 

 

5,572

 

 

 

29,237

 

 

 

22,379

 

General and administrative

 

 

27,568

 

 

 

21,539

 

 

 

98,192

 

 

 

113,662

 

Total operating expenses

 

 

143,942

 

 

 

83,663

 

 

 

477,419

 

 

 

319,536

 

Loss from operations

 

 

(11,605

)

 

 

(21,565

)

 

 

(68,697

)

 

 

(115,042

)

Other income (expense):

 

 

 

 

 

 

 

 

Change in fair value of liabilities

 

 

(942

)

 

 

(9,808

)

 

 

70

 

 

 

3,802

 

Other income, net

 

 

1,519

 

 

 

125

 

 

 

2,918

 

 

 

445

 

Total other income (expense), net

 

 

577

 

 

 

(9,683

)

 

 

2,988

 

 

 

4,247

 

Loss before income taxes

 

 

(11,028

)

 

 

(31,248

)

 

 

(65,709

)

 

 

(110,795

)

Benefit from income taxes

 

 

121

 

 

 

87

 

 

 

31

 

 

 

3,136

 

Net loss

 

 

(10,907

)

 

 

(31,161

)

 

 

(65,678

)

 

 

(107,659

)

Other comprehensive income (loss)

 

 

185

 

 

 

(85

)

 

 

(140

)

 

 

(126

)

Total comprehensive loss

 

$

(10,722

)

 

$

(31,246

)

 

$

(65,818

)

 

$

(107,785

)

Net loss per share attributable to common stockholders:

 

 

 

 

 

 

 

 

Basic and diluted

 

$

(0.05

)

 

$

(0.15

)

 

$

(0.32

)

 

$

(0.58

)

Weighted average shares outstanding:

 

 

 

 

 

 

 

 

Basic and diluted

 

 

206,140,283

 

 

 

201,363,338

 

 

 

204,516,120

 

 

 

186,781,537

 

______________

(1) Includes stock-based compensation expense as follows (in thousands):

 

 

 

Three Months Ended

December 31,

 

Year Ended

December 31,

 

 

2022

 

2021

 

2022

 

2021

Marketing

 

$

1,512

 

$

4,718

 

$

4,648

 

$

9,664

Operations and support

 

 

836

 

 

 

302

 

 

 

2,684

 

 

 

2,735

 

Technology and development

 

 

1,328

 

 

 

989

 

 

 

4,327

 

 

 

4,481

 

General and administrative

 

 

8,674

 

 

 

5,943

 

 

 

31,158

 

 

 

50,331

 

Total stock-based compensation expense

 

$

12,350

 

 

$

11,952

 

 

$

42,817

 

 

$

67,211

 

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(In Thousands, Unaudited)

 

 

Year Ended December 31,

 

2022

 

2021

Operating activities

 

 

 

Net loss

$

(65,678

)

 

$

(107,659

)

Adjustments to reconcile net loss to net cash used in operating activities:

 

 

 

Depreciation and amortization

 

7,474

 

 

 

4,075

 

Stock-based compensation

 

42,817

 

 

 

67,211

 

Change in fair value of liabilities

 

(70

)

 

 

(3,802

)

Warrant expense in connection with Merger

 

 

 

 

154

 

Amortization of debt issuance costs

 

 

 

 

144

 

Net amortization on securities

 

146

 

 

 

2,166

 

Benefit for deferred taxes

 

(594

)

 

 

(3,388

)

Impairment of long-lived assets

 

1,127

 

 

 

 

Non-cash operating lease cost

 

1,605

 

 

 

1,510

 

Non-cash acquisition-related costs

 

837

 

 

 

1,182

 

Non-cash other

 

 

 

 

540

 

Changes in operating assets and liabilities:

 

 

 

Inventory

 

(8,004

)

 

 

(9,628

)

Prepaid expenses and other current assets

 

(6,335

)

 

 

3,200

 

Other long-term assets

 

17

 

 

 

(58

)

Accounts payable

 

12,723

 

 

 

9,853

 

Accrued liabilities

 

909

 

 

 

197

 

Deferred revenue

 

(1,716

)

 

 

1,412

 

Operating lease liabilities

 

(1,605

)

 

 

(1,521

)

Earn-out payable

 

(10,184

)

 

 

 

Net cash used in operating activities

 

(26,531

)

 

 

(34,412

)

Investing activities

 

 

 

Purchases of investments

 

(187,700

)

 

 

(266,633

)

Maturities of investments

 

194,259

 

 

 

158,375

 

Proceeds from sales of investments

 

35,846

 

 

 

3,465

 

Investment in website and mobile application development and internal-use software

 

(4,533

)

 

 

(4,175

)

Purchases of property, equipment, and intangible assets

 

(2,714

)

 

 

(832

)

Deferred consideration paid for acquisitions

 

(459

)

 

 

 

Acquisition of businesses, net of cash acquired

 

 

 

 

(46,468

)

Net cash provided by (used in) investing activities

 

34,699

 

 

 

(156,268

)

Financing activities

 

 

 

Pre-closing stock repurchase

 

 

 

 

(22,027

)

Proceeds from issuance of common stock upon Merger

 

 

 

 

197,686

 

Proceeds from PIPE

 

 

 

 

75,000

 

Payments for transaction costs related to securities issuances

 

 

 

 

(12,851

)

Proceeds from repayment of promissory notes associated with vested and unvested shares

 

 

 

 

1,193

 

Proceeds from exercise of Class A common stock warrants, net of redemption payments

 

 

 

 

787

 

Proceeds from exercise of vested and unvested stock options, net of repurchases and cancelations

 

2,246

 

 

 

1,253

 

Payments for taxes related to net share settlement of equity awards

 

(3,901

)

 

 

(5,998

)

Payments for earn-out consideration for acquisitions

 

(32,650

)

 

 

 

Proceeds from employee stock purchase plan

 

1,178

 

 

 

 

Net cash (used in) provided by financing activities

 

(33,127

)

 

 

235,043

 

Foreign currency effect on cash and cash equivalents

 

(53

)

 

 

(73

)

(Decrease) increase in cash, cash equivalents, and restricted cash

 

(25,012

)

 

 

44,290

 

Cash, cash equivalents, and restricted cash at beginning of period

 

72,640

 

 

 

28,350

 

Cash, cash equivalents, and restricted cash at end of period

$

47,628

 

 

$

72,640

 

Reconciliation of cash, cash equivalents, and restricted cash

 

 

 

Cash and cash equivalents

$

46,772

 

 

$

71,784

 

Restricted cash

 

856

 

 

 

856

 

Total cash, cash equivalents, and restricted cash

$

47,628

 

 

$

72,640

 

Supplemental disclosures of cash flow information

 

 

 

Cash paid for taxes

$

636

 

 

$

338

 

Non-cash investing and financing activities

 

 

 

Recapitalization of redeemable convertible preferred stock from pre-closing stock repurchase

 

 

 

 

125

 

Conversion of redeemable convertible preferred stock to common stock

 

 

 

 

249,837

 

Assumption of Merger warrants liability

 

 

 

 

51,814

 

Redemption/exercise of Class A common stock warrants

 

 

 

 

37,834

 

Conversion of Series D preferred stock warrants to Class A common warrants

 

 

 

 

1,160

 

Right-of-use asset obtained in exchange for lease liability

 

1,206

 

 

 

 

Vesting of early-exercised stock options, net of cancelations

 

197

 

 

 

227

 

Common stock issued, contingent consideration, and liabilities assumed in acquisition of businesses

 

 

 

 

99,958

 

Non-GAAP Financial Measures

In addition to our financial results determined in accordance with U.S. GAAP, we present Adjusted EBITDA (which is a non-GAAP financial measure), and Adjusted EBITDA margin (which is a non-GAAP ratio), each as defined below. We use Adjusted EBITDA and Adjusted EBITDA margin to evaluate our ongoing operations and for internal planning and forecasting purposes. We believe that Adjusted EBITDA and Adjusted EBITDA margin, when taken together with the corresponding U.S. GAAP financial measures, provide meaningful supplemental information regarding our performance by excluding certain items that may not be indicative of our business, results of operations, or outlook. We consider Adjusted EBITDA and Adjusted EBITDA margin to be important measures because they help illustrate underlying trends in our business and our historical operating performance on a more consistent basis. We believe that the use of Adjusted EBITDA and Adjusted EBITDA margin is helpful to our investors as they are used by management in assessing the health of our business and our operating performance.

However, non-GAAP financial information is presented for supplemental informational purposes only, has limitations as an analytical tool, and should not be considered in isolation or as a substitute for financial information presented in accordance with U.S. GAAP. In addition, other companies, including companies in our industry, may calculate similarly-titled non-GAAP financial measures or ratios differently or may use other financial measures or ratios to evaluate their performance, all of which could reduce the usefulness of Adjusted EBITDA or Adjusted EBITDA margin as tools for comparison. Reconciliations are provided below to the most directly comparable financial measures stated in accordance with U.S. GAAP. Investors are encouraged to review our U.S. GAAP financial measures and not to rely on any single financial measure to evaluate our business.

Adjusted EBITDA is a key performance measure that our management uses to assess our operating performance. Because Adjusted EBITDA facilitates internal comparisons of our historical operating performance on a more consistent basis, we use this measure for business planning purposes. “Adjusted EBITDA” is defined as net loss before stock-based compensation, depreciation and amortization, acquisition-related costs (which includes (i) acquisition professional services; and (ii) consideration paid for employee compensation with vesting requirements incurred directly as a result of acquisitions, inclusive of revaluation of earn-out consideration recorded in general and administrative expenses), impairment of long-lived assets, income taxes, change in fair value of liabilities, net interest, one-time bonuses and warrant expense in connection with the combination of Hims, Inc. (“Hims”) and Oaktree Acquisition Corp. (“OAC”), with Hims continuing as the surviving entity and as a wholly-owned subsidiary of OAC, which changed its name to Hims & Hers Health, Inc. (the “Merger”), and amortization of debt issuance costs. “Adjusted EBITDA margin” is defined as Adjusted EBITDA divided by revenue.

Some of the limitations of Adjusted EBITDA include (i) Adjusted EBITDA does not properly reflect capital commitments to be paid in the future, and (ii) although depreciation and amortization are non-cash charges, the underlying assets may need to be replaced and Adjusted EBITDA does not reflect these capital expenditures. In evaluating Adjusted EBITDA, you should be aware that in the future we will incur expenses similar to the adjustments in this presentation. Our presentation of Adjusted EBITDA should not be construed as an inference that our future results will be unaffected by these expenses or any unusual or non-recurring items. We compensate for these limitations by providing specific information regarding the U.S. GAAP items excluded from Adjusted EBITDA. When evaluating our performance, you should consider Adjusted EBITDA in addition to, and not a substitute for, other financial performance measures, including our net loss and other U.S. GAAP results.

Net Loss to Adjusted EBITDA Reconciliation
(In Thousands, Unaudited)

 

Three Months Ended

December 31,

 

Year Ended

December 31,

 

2022

 

2021

 

2022

 

2021

 

 

 

 

 

 

 

 

Revenue

$

167,203

 

 

$

84,699

 

 

$

526,916

 

 

$

271,878

 

 

 

 

 

 

 

 

 

Net loss

 

(10,907

)

 

 

(31,161

)

 

 

(65,678

)

 

 

(107,659

)

Stock-based compensation

 

12,350

 

 

 

11,952

 

 

 

42,817

 

 

 

67,211

 

Depreciation and amortization

 

2,010

 

 

 

1,630

 

 

 

7,474

 

 

 

4,075

 

Acquisition-related costs

 

1,117

 

 

 

891

 

 

 

1,192

 

 

 

8,105

 

Impairment of long-lived assets

 

 

 

 

 

 

 

1,127

 

 

 

 

(Benefit) provision for income taxes

 

(121

)

 

 

(87

)

 

 

(31

)

 

 

(3,136

)

Change in fair value of liabilities

 

942

 

 

 

9,808

 

 

 

(70

)

 

 

(3,802

)

Interest (income) / expense, net

 

(1,472

)

 

 

(92

)

 

 

(2,610

)

 

 

(390

)

Merger bonuses

 

 

 

 

 

 

 

 

 

 

5,219

 

Warrant expense in connection with Merger

 

 

 

 

 

 

 

 

 

 

154

 

Amortization of debt issuance costs

 

 

 

 

 

 

 

 

 

 

144

 

Adjusted EBITDA

$

3,919

 

 

$

(7,059

)

 

$

(15,779

)

 

$

(30,079

)

 

 

 

 

 

 

 

 

Net loss as a % of revenue

 

(7

)%

 

 

(37

)%

 

 

(12

)%

 

 

(40

)%

Adjusted EBITDA margin

 

2

%

 

 

(8

)%

 

 

(3

)%

 

 

(11

)%

 

Investor Relations
Alice Lopatto
Investors@forhims.com

Media Relations
Press@forhims.com

Source: Hims & Hers Health, Inc.